| 0.615 -0.017 (-2.69%) | 01-27 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.79 | 1-year : | 0.86 |
| Resists | First : | 0.67 | Second : | 0.74 |
| Pivot price | 0.65 |
|||
| Supports | First : | 0.57 | Second : | 0.47 |
| MAs | MA(5) : | 0.61 |
MA(20) : | 0.65 |
| MA(100) : | 0.73 |
MA(250) : | 0.75 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 29.4 |
D(3) : | 26.8  |
| RSI | RSI(14): 38 |
|||
| 52-week | High : | 1.7 | Low : | 0.57 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ XLO ] has closed above bottom band by 24.1%. Bollinger Bands are 21.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.64 - 0.64 | 0.64 - 0.65 |
| Low: | 0.6 - 0.6 | 0.6 - 0.6 |
| Close: | 0.61 - 0.62 | 0.62 - 0.62 |
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Fri, 16 Jan 2026
Xilio Therapeutics (NASDAQ: XLO) reverse split vote to keep listing - Stock Titan
Thu, 08 Jan 2026
Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates - Yahoo Finance
Tue, 06 Jan 2026
Xilio Therapeutics Extends Cash Runway Into 2027 - The Globe and Mail
Fri, 26 Dec 2025
Xilio Therapeutics Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis
Mon, 17 Nov 2025
Xilio Therapeutics Reports Revenue Growth Amidst Challenges - TipRanks
Thu, 13 Nov 2025
Xilio Therapeutics, Inc. (XLO) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 68 (M) |
| Shares Float | 28 (M) |
| Held by Insiders | 35.1 (%) |
| Held by Institutions | 23.3 (%) |
| Shares Short | 2,170 (K) |
| Shares Short P.Month | 6,680 (K) |
| EPS | -0.62 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.16 |
| Profit Margin | -183.9 % |
| Operating Margin | -10.2 % |
| Return on Assets (ttm) | -26.3 % |
| Return on Equity (ttm) | -908.3 % |
| Qtrly Rev. Growth | 742.5 % |
| Gross Profit (p.s.) | 0.38 |
| Sales Per Share | 0.47 |
| EBITDA (p.s.) | -0.63 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -17 (M) |
| Levered Free Cash Flow | -21 (M) |
| PE Ratio | -1.01 |
| PEG Ratio | 0 |
| Price to Book value | -3.85 |
| Price to Sales | 1.3 |
| Price to Cash Flow | -2.43 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|